- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
August 2nd, 2007
Domestic anti-cancer drug major Dabur Pharma is finalising plans to enter Japan and China. The company has started the groundwork of filing drug applications and is scouting for potential pharma acquisitions in both the countries.
Dabur Pharma also plans to expand the range of products developed on its nanotechnology drug delivery system, christened ‘Nanoxel'. At the moment, it sells the popular anti-cancer drug ‘Paclitaxel' on this platform. "We also want to export this portfolio of drugs in US, Europe and South-east Asian markets," said Mr Vij.
|Related News Press|
Small but heading for the big time: Nanobiotix half year results for the six months ended 30 June 2015, in line with expectations: Major clinical achievements and corporate developments August 28th, 2015
An engineered surface unsticks sticky water droplets August 31st, 2015
New material science research may advance tech tools August 31st, 2015
Keysight Technologies Begins Trading as Independent Company November 3rd, 2014